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Background. Syphilis infection may potentiate transmission of human immunodeﬁciency virus (HIV). We
sought to determine the extent to which HIV acquisition was associated with syphilis infection within an HIV pre-
exposure prophylaxis (PrEP) trial and whether emtricitabine/tenofovir (FTC/TDF) modiﬁed that association.
Methods. The Preexposure Prophylaxis Initiative (iPrEx) study randomly assigned 2499 HIV-seronegative men
and transgender women who have sex with men (MSM) to receive oral daily FTC/TDF or placebo. Syphilis preva-
lence at screening and incidence during follow-up were measured. Hazard ratios for the effect of incident syphilis on
HIV acquisition were calculated. The effect of FTC/TDF on incident syphilis and HIV acquisition was assessed.
Results. Of 2499 individuals, 360 (14.4%) had a positive rapid plasma reagin test at screening; 333 (92.5%) had a
positive conﬁrmatory test, which did not differ between the arms (FTC/TDF vs placebo, P=.81). The overall syphilis
incidence during the trial was 7.3 cases per 100 person-years. There was no difference in syphilis incidence between
the study arms (7.8 cases per 100 person-years for FTC/TDF vs 6.8 cases per 100 person-years for placebo, P= .304).
HIV incidence varied by incident syphilis (2.8 cases per 100 person-years for no syphilis vs 8.0 cases per 100 person-
years for incident syphilis), reﬂecting a hazard ratio of 2.6 (95% conﬁdence interval, 1.6–4.4; P<.001). There was no
evidence for interaction between randomization to the FTC/TDF arm and incident syphilis on HIV incidence.
Conclusions. In HIV-seronegative MSM, syphilis infection was associated with HIV acquisition in this PrEP
trial; a syphilis diagnosis should prompt providers to offer PrEP unless otherwise contraindicated.
Keywords. chemoprophylaxis; HIV prevention; MSM; preexposure prophylaxis; syphilis.
Approximately 10 million syphilis infections were diag-
nosed in 2008 according to the World Health Organiza-
tion (WHO), many of which occurred in men who have
sex with men or individuals coinfected with human im-
munodeﬁciencyvirus(HIV)[1].The association ofsyph-
ilis and HIV may be causal, as syphilis can facilitate HIV
acquisition [2–8] via mucosal disruption, ulceration [9],
or inﬂammation [10] and HIV transmission by increas-
ing HIV RNA in blood and genital secretions [11].Alter-
natively, the association could be due to increased sexual
risk behaviors or participation in networks with high
prevalence of HIV. Observational evidence from retro-
spective analyses suggests an association between syphilis
and HIV acquisition [12], but few studies have assessed
this association among a closed, prospective cohort of
MSM with almost complete follow-up.
The Preexposure Prophylaxis Initiative (iPrEx) trial
[13]a n do t h e r s[ 14–16] demonstrated the efﬁcacy of
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(FTC/TDF) in preventing HIV acquisition. The iPrEx study pro-
spectively followed a diverse cohort of men and transgender
women who have sex with men (MSM) with frequent sexually
transmitted infection (STI) and HIV testing and offers a unique
opportunity to assess the relationship between syphilis and HIV
acquisition in the context of FTC/TDF preexposure prophylaxis
(PrEP) use. Syphilis provides an informative marker of height-
ened HIV risk and may be an important consideration in assess-
ing the need for PrEP. It is also critical to determine whether
syphilisdecreasesPrEPefﬁcacy,whichcouldresultfromcompro-
mising mucosal barriers, increasing HIV inoculum size [17], or
decreasing PrEP adherence.
In the present study, we determined rates and correlates of
prevalent and incident syphilis in the iPrEx study, the extent
to which incident syphilis was associated with HIV acquisition,
and whether that association varied by treatment group or by
level of adherence (as measured by detected drug) among par-
ticipants in the active arm.
METHODS
Participants and Specimens
The iPrEx study enrolled 2499 HIV-seronegative MSM to eval-
uate the safetyand efﬁcacy of once-daily oral FTC/TDF for HIV
prevention [13].Study visits were scheduled every 4 weeks after
enrollment. The details of the primary study and visits have
been described elsewhere [13]. In a subset of participants sam-
pled from the active arm including longitudinal samples from
HIV-positive cases with site-matched controls, longitudinal
samples from participants enrolled in a bone mineral density
substudy, and cross-sectional samples of participants at weeks
8 and 24, plasma was tested for the presence of FTC and
TDF, and peripheral blood mononuclear cells (PBMCs) were
tested for FTC triphosphate (FTC-TP) and tenofovir diphos-
phate (TFV-DP), as described elsewhere [18]. Diagnosis and
treatment of symptomatic STIs occurred at every visit. At
screening and at 24-week intervals during follow-up, partici-
pants were screened for asymptomatic urethritis, syphilis, and
antibodies to herpes simplex virus type 2 (HSV-2), and they
were examined for genital warts and ulcers. In addition, partici-
pants could presentforan interimvisitonanas-neededbasisfol-
lowing a possible exposure, onset of new symptoms, or STI
treatment. Partners of participants with a curable STI were of-
fered evaluation and treatment.
Syphilis diagnoses were based on standard algorithms ac-
cording to local guidelines or developed by normative bodies
[19] and included an initial nonspeciﬁct e s t —either a rapid
plasma reagin (RPR) test (bioMérieux, Marcy l’Etoile, France;
Becton, Dickinson and Company, Franklin Lakes, New Jersey;
Laborclin, Sao Paolo, Brazil; WAMA Diagnostica, Sao Paolo,
Brazil) or Venereal Disease Research Laboratory (VDRL) test
(Standard Diagnostics, Kyonggi‐do, South Korea) performed
at local sites. Specimens with a newly positive RPR or VDRL re-
sult were sent for conﬁrmatory testing using ﬂuorescent trepo-
nemal antibody-absorption (FTA-ABS) (Biokit, Barcelona,
Spain; Fujirebio Inc, Tokyo, Japan; Zeus Scientiﬁc, Somerville,
New Jersey; bioMérieux; WAMA Diagnostica).
Participants diagnosed with prevalent and incident syphilis
(see deﬁnitions below) were treated in accordance with local
guidelines, or if not available, according to the 2006 sexually
transmitted disease guidelines of the Centers for Disease Con-
trol and Prevention (CDC) [19]. Evaluation and treatment were
managed by the local treating physician under the supervision
of the site investigator. Each incident casewas also reviewed bya
studywide clinical monitoring committee to ensure that appro-
priate guidance for clinical management was provided.
Deﬁnitions
At screening, we examined the number of participants with a
positive RPR result and a positive conﬁrmatory test, which
was deﬁned as syphilis prevalence. Patients newly diagnosed
with syphilis were treated and their serological response was
subsequently monitored. At follow-up, incident syphilis was de-
ﬁned as (1) a change in serology from negative to positive with
conﬁrmation by FTA-ABS, or (2) at least a 4-fold increase in
serological titer from prior test with documentation of prior
treatment appropriate for the stage of syphilis.
Person-time was calculated for participants with incident
syphilis as time between enrollment and ﬁrst episode and for
HIV as the time between enrollment and ﬁrst evidence of HIV
infection. For participants without syphilis, person-time was cal-
culated as years between enrollment and the date of last syphilis
test. Those with conﬁrmed syphilis at screening without clear
documentation of prior effective treatment were treated and
were excluded from the analysis of syphilis incidence, unless
clear documentation of prior effective treatment was available.
Detected drug was deﬁned as the detection of FTC or TDF in
plasma orFTC-TPorTFV-DP inPBMCsregardlessoflevel[18].
Statistical Methods
Baseline characteristics were compared by an unequal-variance
t test for continuous variables and the Fisher exact test for cat-
egorical variables. Syphilis incidencewas calculated as described
above and the results were stratiﬁe db ys i t e ,a g e ,c o n d o m l e s s
insertive or condomless receptive anal intercourse in the past
3 months, reported STI in the past 6 months, HSV-2 positivity,
and syphilis prevalence at screening. Predictors of incident
syphilis were modeled using a stratiﬁed Cox proportional haz-
ards approach.
HIV seroconversion rate was calculated as incident cases
divided by person-years of observation and was stratiﬁed by
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Predictor Total No.
Incident Syphilis (n=279)
P Value No. Person-years Rate
a
Overall 2499 279 3814 7.3
Site <.001
Rio de Janeiro, Brazil (PRACA ONZE) 94 9 82 10.9
Sao Paulo, Brazil (USP) 76 7 67 10.4
Rio de Janeiro, Brazil (FIOCRUZ) 200 26 194 13.4
Lima, Peru (IMPACTA) 440 55 804 6.8
Lima, Peru (INMENSA) 500 60 902 6.7
Iquitos, Peru (ACSA) 460 72 825 8.7
Guayaquil, Ecuador (EQUIDAD) 300 31 470 6.6
San Francisco, California (SFDPH) 140 4 181 2.2
Boston, Massachusetts (Fenway Health) 87 3 101 3.0
Cape Town, South Africa (DTHF) 88 6 81 7.4
Chiang Mai, Thailand (RIHES) 114 6 106 5.6
Education .084
Less than secondary 523 65 762 8.5
Completed secondary 883 107 1372 7.8
Postsecondary 1064 100 1627 6.1
No answer/missing 29 7 54 13.0
Age at screening, y .022
18–24 1254 124 1936 6.4
25–29 514 54 803 6.7
30–39 473 72 728 9.9
≥40 258 29 348 8.3
No. of partners at screening .088
1–3 702 49 960 5.1
4–6 551 65 844 7.7
7–17 624 77 990 7.8
>17 622 88 1021 8.6
Condomless insertive anal intercourse at screening <.001
No 1247 171 1900 9.0
1 partner 809 39 644 6.1
>1 partner 443 69 1270 5.4
Condomless receptive anal intercourse at screening <.001
No 1485 71 1428 5.0
1 partner 814 47 623 7.5
>1 partner 671 161 1763 9.1
Anal intercourse .223
Insertive only 645 20 336 6.0
Receptive 1485 47 623 7.5
No condomless intercourse 369 38 446 8.5
Reported STI in 6 months before screening <.001
Yes 652 127 1103 11.5
No 1847 152 2711 5.6
Transactional sex reported at screening .294
Yes 1027 137 1689 8.1
No 1472 142 2126 6.7
HSV-2–positive at screening <.001
Yes 892 159 1459 10.9
No 1606 120 2355 5.1
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on HIV acquisition were calculated using a Cox proportional
hazards model with incident syphilis as a time-dependent co-
variate stratiﬁed by study site. A bivariate model was evaluated
for the effect of timing of incident syphilis on HIV seroconver-
sion. A multivariate model that evaluated the association of
incident syphilis and HIV seroconversion included study site,
age, race, HSV-2 acquisition (as a time-dependent covariate),
randomization group, condomless sex, and number of partners
at screening and at follow-up; and a history of an STI, syphilis,
HSV-2, HIV-positive partners, and circumcision status at
screening. An interaction hypothesis was prespeciﬁed and test-
ed for detected drug.
RESULTS
Baseline Characteristics, Predictors of Syphilis,
and Syphilis Incidence
Of 2499 individuals, 360 (14.4%) had a positive RPR result at
screening, of whom 333 (92.5%) had a positive conﬁrmatory
test, which did not differ between the arms (FTC/TDF vs place-
bo, P=.81). Fourteen had afalse-positive RPR result and 13 had
no conﬁrmatory testing performed.
Individuals with prevalent syphilis infection at screening
were less educated, were older, and reported having more sexual
partners and more episodes of condomless anal intercourse in
the previous 3 months. The overall syphilis incidence during the
trial was 7.3 cases per 100 person-years, but varied by site, age,
condomless insertive anal intercourse in the past 3 months,
condomless receptive anal intercourse in the past 3 months, re-
ported STI in the past 6 months, HSV-2 positivity, and syphilis
prevalence at screening (Table 1). There was no difference in
syphilis incidence between the study arms (7.8 cases per 100
person-years for FTC/TDF vs 6.8 cases per 100 person-years
for placebo, P= .304).
In a multivariate model that included race, randomization
group, detected drug, number of partners at screening and fol-
low-up, HSV status at screening and follow-up, condomless
insertive anal intercourse at baseline and follow-up, condomless
receptive anal intercourse at baseline and follow-up, history of
an STI at screening, HIV-positive partners at screening, age,
and circumcision status at screening, predictors of incident
syphilis included having antibodies for HSV-2 at screening
and at follow-up (P =. 0 22a n dP = .003, respectively), con-
ﬁrmed syphilis at screening (P <.001), condomless receptive
anal intercourse (P= .006), and condomless insertive anal inter-
course (P=.013). Partner number at screening (P=.769) and at
follow-up (P= .767) was not predictive of incident syphilis.
Syphilis Effect on HIVAcquisition
There were 129 incident HIV infections (excluding 2 partici-
pants who were censored for having syphilis at screening with-
out evidence for effective treatment). HIV incidence varied by
incident syphilis (2.8 cases per 100 person-years for no syphilis
vs 8.0 cases per 100 person-years for incident syphilis), giving a
hazard ratio (HR) of 2.6 (95% conﬁdence interval [CI], 1.6–4.4;
P<.001) (Figure 1). In the bivariate model, HIV incidence also
varied by timing of incident syphilis with respect to HIV
Table 1 continued.
Predictor Total No.
Incident Syphilis (n=279)
P Value No. Person-years Rate
a
Randomized treatment .304
FTC/TDF 1251 147 1886 7.8
Placebo 1248 132 1928 6.8
Syphilis at screening <.001
Positive 333 103 507 20.3
Not positive 2166 176 3307 5.3
Plasma drug levels at week 8 (n=470 samples) .49
Placebo 1248 132 1928 6.8
Drug detected week 8 683
b 68
b 1024
b 6.7
No detected drug week 8 568
b 79
b 896
b 8.8
P value comparing detected drug to no detected drug at week 8 = 0.33.
Abbreviations: ACSA, Asociación Civil Selva Amazónica; DTHF, The Desmond Tutu HIV Foundation; EQUIDAD, Fundación Ecuatoriana Equidad; FIOCRUZ,
Fundação Oswaldo Cruz; FTC/TDF, emtricitabine/tenofovir; HSV-2, herpes simplex virus type 2; IMPACTA, Asociación Civil Impacta Salud y Educación;
INMENSA, Investigaciones Médicas en Salud; PRACA ONZE, Projecto Praça Onze; RIHES, Research Institute for Health Sciences; SFDPH, San Francisco
Department of Public Health; STI, sexually transmitted infection; USP, Universidade de São Paulo.
a Rate per 100 person-years. Excludes 22 patients who were conﬁrmed to be syphilis positive at screening, but lack documentation of adequate treatment.
b Total participants, follow-up, and syphilis events estimated by sampling weights.
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100 person-years for incident syphilis >90 days from HIV sero-
conversion), giving an HR of 3.8 (95% CI, 1.9–7.6; P<.001) for
syphilis ≤90 days vs 2.0 (95% CI, 1.0–4.0; P=.040) for incident
syphilis>90 days.Theseassociations remained signiﬁcantbutdid
not differ from each other signiﬁcantly in a multivariate model
that included study site, race, randomization group, syphilis
at screening, HSV-2 at screening, HSV-2 acquisition (as a
time-dependent covariate), condomless sex (at screening and at
follow-up), number of partners at screening and at follow-up,
historyofanSTIatscreening,HIV-positivepartnersatscreening,
age, and circumcision status (HR for syphilis ≤90 days, 3.4 [95%
CI, 1.7–7.0; P=.001] vs >90 days, 2.1 [95% CI, 1.0–4.2; P=.035];
P =.30 for the interaction). A similar association of incident
syphilis on HIVacquisition was seen among participants without
syphilis at screening and also within each study arm.
Evaluation of Interactions of Incident Syphilis, FTC/TDF,
and HIVAcquisition
There was no evidence for interaction of syphilis on FTC/TDF’s
efﬁcacy. In the modiﬁed intent-to-treat analysis (mITT), FTC/
TDF efﬁcacy was 40% (95% CI, 11%–59%) in the absence of in-
cident syphilis (70 placebo, 40 FTC/TDF), whereas mITT efﬁ-
cacy was 47% (95% CI, <0% to 79%) in the presence of incident
syphilis (12 placebo, 7 FTC/TDF) (P= .98) (Figure 1).
Within the active arm, there was no evidence for interaction
of detected drug on the effect of incident syphilis on HIV inci-
dence. The risk reduction (relative to participants randomized
to the placebo arm and without incident syphilis) for HIV ac-
quisition among participants randomized to the active arm with
no drug detected was 26% among those with incident syphilis
and 11% among those without incident syphilis (P= .71 for the
interaction), whereas the risk reduction for HIV acquisition
among participants randomized to the active arm with detected
drug was 79% among participants with incident syphilis and
88% among those without incident syphilis (P =. 64fo rt he
interaction).
DISCUSSION
In this large randomized placebo-controlled clinical trial of oral
FTC/TDF for PrEP, HIV acquisition was strongly associated
with incident syphilis, and syphilis did not attenuate the protec-
tive beneﬁt of antiretroviral chemoprophylaxis against HIV.
Syphilis infection was highly prevalent at screening (13.3%).
Syphilis incidence during the study period was 7.3 cases per
100 person-years overall, but the rate varied by study site, age,
condomless anal intercourse, recent STI, HSV-2 serostatus, and
syphilis prevalence at screening. The independent effect of
syphilis on HIV acquisition was afﬁrmed in both study arms
and with multivariable analyses that controlled for known pre-
dictors of HIV and other STIs. Predictors of syphilis incidence
were similar to predictors of syphilis prevalence and did not in-
clude randomization group or detectable drug. Even when cases
of incident syphilis that coincided with HIV diagnosis were ex-
cluded (to exclude HIV occurring prior to syphilis in between
study visits), the independent effect of syphilis on HIV acquisi-
tion was still afﬁrmed.
High rates of STIs in other studies of MSM have been consis-
tently associated with incident HIV [12, 20–28]. The impor-
tance of such ﬁndings as they relate to the current study is
highlighted by current estimateso fh i g hs y p h i l i sp r e v a l e n c e
among MSM. Among countries included in iPrEx with avail-
able data, WHO has estimated the following prevalence of syph-
ilis among MSM: Brazil, 13.4% (2010); Ecuador, 6.5% (2010);
and Thailand, 21.6% (2008) [29]. According to the CDC 2011
estimate, the prevalence of syphilis among men visiting CDC
Sexually Transmitted Disease Surveillance Network clinics in
the United States was 2.6% among HIV-negative MSM and
10.1% among HIV-positive MSM [30]. Our data reﬂecting a
study screening prevalence of syphilis of 13.3% are therefore
consistent with global estimates.
The strong independent effect of incident syphilis on HIV
acquisition in this PrEP study suggests the importance of
timely diagnosis and treatment of syphilis among at-risk
MSM to decrease HIV incidence; additionally, a new syphilis
Figure 1. Human immunodeﬁciency virus (HIV) incidence according to in-
cident syphilis and treatment arm. Abbreviation: FTC/TDF, emtricitabine/
tenofovir.
1024 • CID 2014:59 (1 October) • HIV/AIDSdiagnosis offers a key opportunity for PrEP initiation, given the
increased risk for HIV infection among individuals infected
with syphilis. HIV-uninfected individuals who present with
new syphilis infections should be offered PrEP, unless otherwise
contraindicated, in addition to immediate syphilis treatment,
and treatment for their sexual partners.
Furthermore, we found that FTC/TDF had no effect on the
association between incident syphilis and incident HIV.
Concern has been raised that antiretroviral PrEP may lead to
increases in condomless anal sex as aform of risk compensation
in an era of therapeutic optimism [31–33], which may in turn
increase the overall burden of STIs among MSM. Importantly,
within the iPrEx trial, sexual practices reported by participants
trended toward safety over time, even among those who per-
ceived they were on the active arm and believed that the active
arm would be effective [34].Syphilis incidence decreased, more-
over, providing both self-reported and objective laboratory
evidence against risk compensation [34]. Although syphilis in-
cidence was high, it declined overall and in both treatment arms
during iPrEx follow-up. In the current analysis, we found that
the efﬁcacy of FTC/TDF is not affected by syphilis infection.
Study limitations include an inherent underestimation of
syphilis cases because participants were censored at the time
of ﬁrst incident infection and our routine syphilis surveillance
occurred at study screening and every 24 weeks only. Our
study population was composed of MSM and may not be gen-
eralizable to other populations such as heterosexuals or those
outside of a clinical trial setting. The effect of PrEP on syphilis
and HIV incidence demonstrated in this study must be inter-
preted in the context of a randomized clinical trial; the results
of demonstration projects are needed to more deﬁnitively eval-
uate the relationship between syphilis and HIV incidence with
open-label PrEP use. Furthermore, a larger sample size would
provide more power to deﬁnitelyaddress whether syphilis infec-
tion affects PrEP efﬁcacy.
The results of this study demonstrate the striking, increased
HIV incidence associated with incident syphilis infection, an ef-
fect independent of other predictors and unaltered by study
arm. Timely diagnosis and treatment of syphilis infections is
the mainstay of epidemic control in the absence of a vaccine,
and may decrease transmission of HIV [35].A syphilis infection
should trigger a recommendation to start PrEP unless contrain-
dications are present. Creatinine clearance <60 mL/minute and
preexisting HIV infection are the only contraindications listed
in the US Food and Drug Administration–approved informa-
tion from the manufacturer [36]. The CDC recommends that
PrEP be prioritized toward individuals at “very high risk for
HIV acquisition” [37,38]and here we demonstrate that individ-
uals with syphilis fulﬁll that criterion. A recent secondary anal-
ysis of iPrEx data demonstrated a population-attributable
fraction (PAF) for syphilis of approximately 10% with a number
needed to treat of approximately 10 to prevent 1 HIV infection.
Higher PAFs were represented by report of condomless receptive
anal intercourse (PAF=64%) with a partner of unknown HIV
infection status, and reporting >5 sex partners (PAF= 13%)
[39]. Clinicians should prioritize PrEP for individuals at highest
risk, including those infected with syphilis.
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